Candel Therapeutics, Inc.CADLNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
18.24%
↑ 59% above average
Average (22q)
11.48%
Historical baseline
Range
High:94.93%
Low:-44.56%
Volatility
1215.2%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 18.24% |
| Q2 2025 | 74.08% |
| Q1 2025 | -12.16% |
| Q4 2024 | -15.58% |
| Q3 2024 | 8.78% |
| Q2 2024 | 29.29% |
| Q1 2024 | -44.56% |
| Q4 2023 | 18.84% |
| Q3 2023 | -1.50% |
| Q2 2023 | 8.50% |
| Q1 2023 | 10.00% |
| Q4 2022 | -7.51% |
| Q3 2022 | 7.05% |
| Q2 2022 | -7.29% |
| Q1 2022 | 40.56% |
| Q4 2021 | -26.80% |
| Q3 2021 | 59.93% |
| Q2 2021 | 19.58% |
| Q1 2021 | -22.10% |
| Q4 2020 | 94.93% |
| Q3 2020 | 1.00% |
| Q2 2020 | 10.73% |
| Q1 2020 | 0.00% |